Vineet Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

1.86×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.47×	1.47×	0.91×	1.16×	1.17×
0.52×	0.52×	0.23×	0.51×	0.55×
16.7	16.7	0.3	0.2	0.6
31.5	31.5	−7.0	12.2	13.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

VINEETLAB₹37.76

Vineet Laboratories Limited

· Pharma & Health

₹ CrorePeersBIOFILCHEM MANGALAM LASA KREBSBIO ALPA BALPHARMA ORTINGLOBE NATCAPSUQMcap ₹72.5 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	1.86
Current Ratio	1.17	1.16	0.91	1.47	1.47
Quick Ratio	0.55	0.51	0.23	0.52	0.52
Cash, Equiv & ST Investments	0.6	0.2	0.3	16.7	16.7
Working Capital	13.0	12.2	-7.0	31.5	31.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.